JP2019526270A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526270A5
JP2019526270A5 JP2019513999A JP2019513999A JP2019526270A5 JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5 JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019513999 A JP2019513999 A JP 2019513999A JP 2019526270 A5 JP2019526270 A5 JP 2019526270A5
Authority
JP
Japan
Prior art keywords
bcr
nucleic acid
acid encoding
primary
therapeutic cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019513999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051182 external-priority patent/WO2018049401A1/en
Publication of JP2019526270A publication Critical patent/JP2019526270A/ja
Publication of JP2019526270A5 publication Critical patent/JP2019526270A5/ja
Priority to JP2022162584A priority Critical patent/JP2022189863A/ja
Withdrawn legal-status Critical Current

Links

JP2019513999A 2016-09-12 2017-09-12 ゲノム編集初代b細胞ならびに作製方法および使用方法 Withdrawn JP2019526270A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022162584A JP2022189863A (ja) 2016-09-12 2022-10-07 ゲノム編集初代b細胞ならびに作製方法および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393512P 2016-09-12 2016-09-12
US62/393,512 2016-09-12
PCT/US2017/051182 WO2018049401A1 (en) 2016-09-12 2017-09-12 Genome edited primary b cell and methods of making and using

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162584A Division JP2022189863A (ja) 2016-09-12 2022-10-07 ゲノム編集初代b細胞ならびに作製方法および使用方法

Publications (2)

Publication Number Publication Date
JP2019526270A JP2019526270A (ja) 2019-09-19
JP2019526270A5 true JP2019526270A5 (enExample) 2020-10-22

Family

ID=61562180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019513999A Withdrawn JP2019526270A (ja) 2016-09-12 2017-09-12 ゲノム編集初代b細胞ならびに作製方法および使用方法
JP2022162584A Pending JP2022189863A (ja) 2016-09-12 2022-10-07 ゲノム編集初代b細胞ならびに作製方法および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022162584A Pending JP2022189863A (ja) 2016-09-12 2022-10-07 ゲノム編集初代b細胞ならびに作製方法および使用方法

Country Status (7)

Country Link
US (1) US20220168342A1 (enExample)
EP (1) EP3509606A4 (enExample)
JP (2) JP2019526270A (enExample)
CN (1) CN109843303A (enExample)
AU (1) AU2017322733B2 (enExample)
CA (1) CA3036820A1 (enExample)
WO (1) WO2018049401A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018235957B2 (en) 2017-03-16 2024-02-01 Seattle Children's Hospital (dba Seattle Children's Research Institute) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
AU2020392222A1 (en) * 2019-11-27 2022-06-09 Board Of Regents, The University Of Texas System Large-scale combined CAR transduction and CRISPR gene editing of B cells
WO2023283585A2 (en) * 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
WO2023010125A1 (en) * 2021-07-29 2023-02-02 Regents Of The University Of Minnesota Multiplex base editing of primary human natural killer cells
EP4555091A2 (en) * 2022-07-13 2025-05-21 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024196669A2 (en) * 2023-03-17 2024-09-26 Walking Fish Therapeutics, Inc. Methods for in vivo editing of b cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170354681A1 (en) * 2014-10-24 2017-12-14 Bcrt Holding Bv T cell-based immunotherapeutics
EP4177336A1 (en) * 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells

Similar Documents

Publication Publication Date Title
JP2019526270A5 (enExample)
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CY1123028T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
CA3045233A1 (en) Novel t cell receptors and immune therapy using the same
EP4032544A3 (en) Novel t cell receptors and immune therapy using the same
JP2010227108A5 (enExample)
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
MY189035A (en) Antibody for binding to interleukin 4 receptor
WO2018104909A3 (en) Dna methylation profiling for t-cell immunotherapy
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
RU2018132044A (ru) Антитела против тау
JP2011152135A5 (enExample)
MX366206B (es) Vacuna de antígeno micobacteriano.
EA201370076A1 (ru) Иммуноглобулины-переносчики и их применение
JP2016510594A5 (enExample)
JP2013539454A5 (enExample)
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
EP4279136A3 (en) Methods for determining car-t cells dosing
FI3792628T3 (fi) Menetelmiä neoantigeenien hyödyllisyyden ennustamiseen immunoterapiassa
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
WO2016100328A8 (en) Novel tilapia virus and uses thereof
JP2018023397A5 (enExample)
HRP20230605T1 (hr) Protutijela protiv interferona beta i njihova upotreba